Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis
, , , , , y
19 jun 2024
Acerca de este artículo
Publicado en línea: 19 jun 2024
Páginas: 90 - 96
DOI: https://doi.org/10.2478/pneum-2024-0014
Palabras clave
© 2023 Victoria Țau et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Țau, Victoria
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Antal, Andreea Zabară
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Doctoral School, Faculty of Medicine, University of Medicine and Pharmacy “Grigore T. Popa”Iași, Romania
Antohi, Paula Vasilache
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Stoian, Ioana Adelina
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Doctoral School, Faculty of Medicine, University of Medicine and Pharmacy “Grigore T. Popa”Iași, Romania
Pintilie, Adriana Loredana
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Trofor, Antigona Carmen
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Pulmonary Department, Faculty of General Medicine, University of Medicine and Pharmacy “Grigore T. Popa,”Iași, Romania
Crișan-Dabija, Radu Adrian
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Pulmonary Department, Faculty of General Medicine, University of Medicine and Pharmacy “Grigore T. Popa,”Iași, Romania